• 1. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 2. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 3. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 4. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 5. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ketones
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbonyl compounds Ketones

Introduction to 2H,3H-furo[3,2-b]pyridin-3-one (CAS No. 119293-03-7)

2H,3H-furo[3,2-b]pyridin-3-one, identified by the chemical compound code CAS No. 119293-03-7, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology due to its unique structural framework and potential biological activities. This compound belongs to the class of fused heterocycles, combining a furan ring with a pyridine core, which creates a versatile scaffold for drug design and development. The presence of both nitrogen and oxygen atoms in its structure imparts distinct electronic and steric properties, making it a promising candidate for various therapeutic applications.

The molecular structure of 2H,3H-furo[3,2-b]pyridin-3-one consists of a furan ring fused to a pyridine ring at the 3-position of the furan, with an additional carbonyl group at the 3-position of the pyridine ring. This specific arrangement of functional groups allows for diverse chemical modifications, enabling the synthesis of derivatives with tailored biological properties. The compound’s ability to interact with biological targets through hydrogen bonding and other non-covalent interactions makes it an attractive scaffold for developing novel therapeutic agents.

In recent years, there has been growing interest in exploring the pharmacological potential of furo[3,2-b]pyridinone derivatives. The unique structural features of this scaffold have been leveraged to develop compounds with anti-inflammatory, anticancer, and antimicrobial properties. For instance, studies have shown that certain derivatives of 2H,3H-furo[3,2-b]pyridin-3-one exhibit significant inhibitory effects on enzymes involved in inflammatory pathways, such as cyclooxygenase (COX) and lipoxygenase (LOX). These findings highlight the compound’s potential as a lead molecule for developing new anti-inflammatory drugs.

Moreover, the fused heterocyclic system in 2H,3H-furo[3,2-b]pyridin-3-one has been investigated for its anticancer properties. Research indicates that derivatives of this compound can selectively inhibit the growth of cancer cells by targeting key molecular pathways involved in cell proliferation and survival. For example, some furo[3,2-b]pyridinone derivatives have demonstrated potent activity against breast cancer and leukemia cell lines by inducing apoptosis and inhibiting tumor angiogenesis. These preclinical findings suggest that further exploration of this scaffold could lead to the discovery of novel anticancer therapeutics.

The antimicrobial potential of 2H,3H-furo[3,2-b]pyridin-3-one has also been explored in recent studies. Furan-based compounds are known for their ability to disrupt bacterial cell membranes and inhibit microbial growth. Preliminary research has shown that certain derivatives of this compound exhibit broad-spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria as well as fungi. This makes it a promising candidate for developing new antimicrobial agents to combat drug-resistant infections.

The synthesis of 2H,3H-furo[3,2-b]pyridin-3-one involves multi-step organic reactions that require careful optimization to achieve high yields and purity. Common synthetic routes include cyclization reactions followed by functional group transformations to introduce the desired substituents. Advances in synthetic methodologies have enabled the efficient preparation of complex derivatives of this scaffold, facilitating their exploration in drug discovery programs.

The pharmacokinetic properties of furo[3,2-b]pyridinone derivatives are also an important consideration in drug development. Studies have shown that these compounds can exhibit favorable solubility and bioavailability profiles when properly designed. Additionally, their metabolic stability can be enhanced through structural modifications to improve their therapeutic efficacy and reduce side effects.

In conclusion,2H,3H-furo[3,2-b]pyridin-3-one (CAS No. 119293-03-7) represents a structurally interesting and biologically relevant scaffold with significant potential in pharmaceutical research. Its unique combination of functional groups and its ability to interact with various biological targets make it a valuable starting point for developing novel therapeutic agents. As research continues to uncover new applications for this compound and its derivatives,furo[3,2-b]pyridinone-based drugs are likely to play an increasingly important role in addressing unmet medical needs across multiple therapeutic areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)